CDRH Mulls Increased Human Factors Input In Premarket Review Process
This article was originally published in The Gray Sheet
Executive Summary
CDRH Office of Device Evaluation Director Donna-Bea Tillman, PhD, says she plans to consider whether review staffers need to consult more often with the human factors engineering team
You may also be interested in...
CDRH General Hospital Devices Branch Takes On Software Applications
Increased submissions for medically-related software products are prompting CDRH's General Hospital Devices Branch to establish a premarket regulatory framework for the devices
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.